Get the Stockscreener App
529.95
2.40%
-13.04
Argen X Se Adr stock is traded at $529.95, with a volume of 310.32K.
It is down -2.40% in the last 24 hours and up +0.48% over the past month.
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
See More
Previous Close:
$542.99
Open:
$531.78
24h Volume:
310.32K
Relative Volume:
1.00
Market Cap:
$31.69B
Revenue:
$1.62B
Net Income/Loss:
$-204.35M
P/E Ratio:
-127.39
EPS:
-4.16
Net Cash Flow:
$-1.28B
1W Performance:
-1.15%
1M Performance:
+0.48%
6M Performance:
+36.98%
1Y Performance:
+11.19%
1-Day Range:
$522.93
$543.18
1-Week Range:
$522.93
$552.00
52-Week Range:
$327.73
$554.74
Argen X Se Adr Stock (ARGX) Company Profile
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-20-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-31-23 | Initiated | Scotiabank | Sector Perform |
| Jul-24-23 | Downgrade | UBS | Buy → Neutral |
| Jul-17-23 | Resumed | Evercore ISI | Outperform |
| Jun-15-23 | Initiated | Societe Generale | Sell |
| May-31-23 | Initiated | UBS | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-14-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-07-22 | Initiated | William Blair | Outperform |
| Oct-12-22 | Initiated | Oppenheimer | Perform |
| Jul-29-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-22 | Resumed | Stifel | Buy |
| May-03-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-29-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-23-21 | Upgrade | Redburn | Neutral → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-23-21 | Initiated | Deutsche Bank | Hold |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-18-21 | Initiated | UBS | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-23-21 | Initiated | Redburn | Neutral |
| Mar-05-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-21 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-20 | Initiated | H.C. Wainwright | Neutral |
| Feb-10-20 | Initiated | BofA/Merrill | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Oct-31-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-22-19 | Initiated | JP Morgan | Overweight |
| Sep-27-19 | Initiated | Wells Fargo | Market Perform |
| Sep-16-19 | Resumed | Cowen | Outperform |
| Jun-28-19 | Initiated | Robert W. Baird | Outperform |
| Jan-18-19 | Resumed | SunTrust | Buy |
| Jan-04-19 | Initiated | Morgan Stanley | Overweight |
| Dec-17-18 | Initiated | Goldman | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Jun-29-18 | Initiated | Nomura | Buy |
| Apr-09-18 | Initiated | SunTrust | Buy |
| Jan-29-18 | Reiterated | JMP Securities | Mkt Outperform |
View All
Argen X Se Adr Stock (ARGX) Latest News
Deutsche Bank downgrades argenx shares, keeping price target steady amid incremental caution - Investing.com India
Deutsche Bank downgrades argenx shares, keeping price target steady amid incremental caution - Investing.com
Halozyme expands argenx collaboration with $30M deal - Investing.com
Biotech Leader Argenx In Buy Zone, Poised To Hit New Highs - Investor's Business Daily
Weekly Upgrades and Downgrades - InvestorPlace
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases - Investor's Business Daily
Baird sustains price target on Argenx shares, cites competition - Investing.com
Piper Sandler maintains Overweight rating on argenx shares - Investing.com
argenx ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily
Argen X SE ADR (ARGX) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Four Biotech Stocks Rally Toward Buy Points As Funds Load Up - Investor's Business Daily
Argenx stock soars to 52-week high, hits $540.74 - Investing.com India
Argenx stock soars to 52-week high, hits $540.74 - Investing.com
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB - Benzinga
Argen X SE ADR (ARGX) is looking forward to a strong quarter - SETE News
Argenx stock hits 52-week high at $533.88 amid robust growth - Investing.com India
Argenx stock hits 52-week high at $533.88 amid robust growth - Investing.com
Barclays upgrades argenx stock on promising Vyvgart outlook - Investing.com
Stocks With Rising Relative Price Strength: argenx ADR - Investor's Business Daily
Baird raises argenx shares target on strong revenue and FDA progress - Investing.com
Argen X SE ADR (ARGX) Outlook: Revisiting The Past For Future Insights - Stocks Register
Envestnet Inc. (ENV) At $62.00: Is It Worth Your Interest? - Stocks Register
Stevanato Group Spa (STVN) Is A Stock Worth Accumulating At Current Levels - Stocks Register
The Behavior Of DXC Technology Co (DXC) Stock Is Not As Predictable As You Think - Stocks Register
At $18.01 Price, Prudential plc ADR (PUK) Sits And Waits For Direction - Stocks Register
Analyst Stifel Price Target And Rating For HilleVax Inc (HLVX) - Stocks Register
Analyzing Vertex Energy Inc’s (VTNR) Stock Behavior - Stocks Register
Mizuho Financial Group, Inc. ADR (MFG): Be Patient, You Will Learn - Stocks Register
GoPro Inc. (GPRO) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Bowlero Corp (BOWL) Worth Considering For The Next Few Weeks - Stocks Register
argenx SE returns to growth driven by Vyvgart, H.C. Wainwright raises shares PT - Investing.com
argenx shares target lifted on revenue growth prospects - Investing.com
Argenx Is Expanding Its Autoimmune Portfolio With New Vyvgart Approvals and Pipeline Candidates - Morningstar
Earnings call: Argenx reported an operating income of $489 million - Investing.com India
Earnings call: Argenx reported an operating income of $489 million - Investing.com
argenx ADR Getting Closer To Key Technical Benchmark - Investor's Business Daily
Oppenheimer upgrades argenx stock rating on CIDP indication - Investing.com
Belgium stocks higher at close of trade; BEL 20 up 1.37% - Investing.com
Truist highlights argenx innovative pipeline as stock catalyst - Investing.com India
Truist highlights argenx innovative pipeline as stock catalyst - Investing.com
argenx SE stock target lifted with Buy rating on growth outlook - Investing.com
Scotiabank holds argenx at Sector Perform with $416 target - Investing.com
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China - Business Wire
argenx and Zai Lab Announce Approval of Efgartigimod Alfa - GlobeNewswire Inc.
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China - Yahoo Finance
Fund managers' favourite health stocks - Investors Chronicle
Barclays maintains Equalweight on argenx stock - Investing.com
Barclays maintains Equalweight on argenx stock - Investing.com India
Jefferies lifts Agnico-Eagle Mines shares target amid rising gold prices By Investing.com - Investing.com UK
Argen X Se Adr Stock (ARGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.40%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):